GNPX
Genprex, Inc.
$0.6400
-2.14%
$7.0M
No data for this timeframe.
Vol
Market Cap$7.0M
Cap SizeNano Cap
Inst. Holders8 funds
Inst. Value$18.7K
Inst. Activity0 buys / 1 sells
Insider Activity0B / 1S
Insider Net $-$9.84
Reddit Sentiment64° Warm
SEC Reports5
Congressional1 trades
Recent Activity
Jun 5, 2026
SEC
Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Meeting, detailing pos
8-K — Impact 3/10
May 14, 2026
SEC
Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA) presented at the
8-K — Impact 4/10
May 13, 2026
earnings_calendar
GNPX Q1 2026 Earnings Scheduled — 2026-05-13
Apr 28, 2026
SEC
Genprex announced that its research collaborators will present positive preclinical data for its diabetes gene therapy c
8-K — Impact 3/10
Apr 14, 2026
Insider
LONGNECKER BRENT M sold 8 shares
Director @ $1.23 ($9.84)
Feb 27, 2026
Insider
Confer Ryan M. surrendered for taxes 9,330 shares
President, CEO and CFO @ $2.00 ($18.7K)
Feb 27, 2026
Insider
Berger Mark Stanley surrendered for taxes 7,168 shares
Chief Medical Officer @ $2.00 ($14.3K)
Inst.
GROUP ONE TRADING LLC — TRIM
1 shares ($2.00)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 17, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 15, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 4, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 3, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 25, 2024 | HC Wainwright & Co. | INITIATE | Buy |
Latest Reports
NEUTRAL
8-K
3/10
Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Meeting, detailing pos
Jun 5, 2026
NEUTRAL
8-K
4/10
Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA) presented at the
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $10.8K | — |
| JONES FINANCIAL COMPANIES LLLP | $3.8K | — |
| CITIGROUP INC | $3.7K | — |
| BlackRock, Inc. | $340.00 | — |
| MORGAN STANLEY | $11.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 14, 2026 | LONGNECKER BRENT | SELL | $9.84 |
| Feb 27, 2026 | Confer Ryan | F | $18.7K |
| Feb 27, 2026 | Berger Mark | F | $14.3K |
Reddit Sentiment
64°▼
Warm
Bearish
Neutral
Bullish
Congressional Trades
1 members: 1 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Timothy Moore | R | BUY | $1,001 - $15,000 |
8 institutional holders with $18.7K total value (10,293 shares) as of 2026-Q1. Top holders: VANGUARD, JONES, CITIGROUP. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 5,950 | $10.8K | 57.7% | — |
| 2 | JONES FINANCIAL COMPANIES LLLP | 2,105 | $3.8K | 20.5% | — |
| 3 | CITIGROUP INC | 2,039 | $3.7K | 19.8% | — |
| 4 | BlackRock, Inc. | 188 | $340.00 | 1.8% | — |
| 5 | MORGAN STANLEY | 6 | $11.00 | 0.1% | — |
| 6 | Allworth Financial LP | 3 | $6.00 | 0.0% | — |
| 7 | GROUP ONE TRADING LLC | 1 | $2.00 | 0.0% | TRIM -50.0% |
| 8 | DANSKE BANK A/S | 1 | $2.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| GROUP ONE TRADING LLC | TRIM | 2 | 1 | -50.0% | $2.00 | 2026-Q1 |
3 unique insiders with 3 transactions. Net insider value: -$9.84 ($0.00 bought, $9.84 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | LONGNECKER BRENT M | Director | SELL | 8 | $1.23 | $9.84 |
| Feb 27, 2026 | Confer Ryan M. | President, CEO and CFO | TAX W/H | 9,330 | $2.00 | $18.7K |
| Feb 27, 2026 | Berger Mark Stanley | Chief Medical Officer | TAX W/H | 7,168 | $2.00 | $14.3K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
3/10
Genprex announced that its research collaborators' abstract was published at the 2026 ASCO Annual Me
Jun 5, 2026
NEUTRAL
8-K
4/10
Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/Ma
May 14, 2026
NEUTRAL
8-K
3/10
Genprex announced that its research collaborators will present positive preclinical data for its dia
Apr 28, 2026
BULLISH
8-K
6/10
Genprex announced a new Sponsored Research Agreement with MD Anderson Cancer Center to study biomark
Apr 21, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 18, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action May 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2025-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 17, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 4, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 3, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 25, 2024 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
1 members of Congress traded this stock: 1 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | Timothy Moore | R | HOUSE | BUY | $1,001 - $15,000 | GENPREX INC | Feb 23, 2026 (19d) |
64°
Warm
Bearish
Neutral
Bullish
7 mentions
5 bullish
2 bearish
7 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 13, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Oct 23, 2024 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$GNPX Timeline Going Forward
▲ 1
💬 1
⚡ 0.5
Gnpx - Read the file, not just the headlines
▲ 1
💬 1
⚡ 0.5
Big Week $GNPX
▲ 1
💬 1
⚡ 0.5
$GNPX NEWS
▲ 8
💬 2
⚡ 0.1
May 13, 2026
earnings_calendar
GNPX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
GNPX Q1 2026 Earnings Scheduled — 2026-05-11
Apr 22, 2026
short_volume
Short Volume: GNPX — 58.1% short (0.5M / 0.9M)
Short: 544,072 | Exempt: 215 | TRF Vol: 936,003 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: GNPX — 65.8% short (2.6M / 3.9M)
Short: 2,552,823 | Exempt: 394,024 | TRF Vol: 3,878,468 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings_calendar
GNPX Q4 2025 Earnings After Market Close — 2026-03-30